HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target
Lyra Therapeutics Analyst Ratings
BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating
Lyra Therapeutics Analyst Ratings
Jefferies Cuts Lyra to Hold in Wake of Failed Phase 3 Study
Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50
Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)
Sell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding Concerns
BTIG Downgrades Lyra Therapeutics (LYRA) to a Hold
Buy Rating Affirmed for Lyra Therapeutics Amid Strong Phase 3 Prospects for LYR-210
Lyra Therapeutics Analyst Ratings
Buy Rating for Lyra Therapeutics Backed by Upcoming Catalysts and Market Potential
Buy Rating Affirmed for Lyra Therapeutics Amid Favorable LYR-210 Trial Outcomes and Strategic CRS Market Positioning
Lyra Therapeutics Analyst Ratings
Lyra Therapeutics Analyst Ratings
Lyra Therapeutics Analyst Ratings
Optimistic Buy Rating for Lyra Therapeutics' LYR-210 Amidst Phase 3 Trial and Market Opportunity
BTIG Keeps Their Buy Rating on Lyra Therapeutics (LYRA)
Lyra Therapeutics' Nasal Implants Show Promising Results: A Buy Rating Supported by Phase 2 BEACON Trial and Upcoming Phase 3 ENLIGHTEN Trial
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (VCEL), Sana Biotechnology (SANA) and Lyra Therapeutics (LYRA)
No Data
No Data